Novel therapeutics in myocardial infarction: Targeting microvascular dysfunction and reperfusion injury

Christopher B. Fordyce, Bernard J. Gersh, Gregg W. Stone, Christopher B. Granger

Research output: Contribution to journalReview articlepeer-review

59 Scopus citations

Abstract

Despite the large number of novel therapies under basic scientific investigation, the translation of cardioprotective strategies targeting reperfusion injury to improve patient outcomes following percutaneous coronary intervention (PCI) for myocardial infarction (MI) has been disappointing. The varying susceptibility of an individual to reperfusion injury, as well as the narrow window of opportunity in which to intervene, adds significant complexity. Here, we discuss the unmet need and challenges of translating cardioprotective strategies into clinical practice, review the pathophysiology of microvascular dysfunction and lethal reperfusion as they relate to promising novel therapeutics, and evaluate recent and ongoing clinical trials in the field.

Original languageEnglish
Pages (from-to)605-616
Number of pages12
JournalTrends in Pharmacological Sciences
Volume36
Issue number9
DOIs
StatePublished - 12 Sep 2015
Externally publishedYes

Keywords

  • coronary microcirculation
  • myocardial infarction
  • novel therapeutics
  • reperfusion injury

Fingerprint

Dive into the research topics of 'Novel therapeutics in myocardial infarction: Targeting microvascular dysfunction and reperfusion injury'. Together they form a unique fingerprint.

Cite this